Effect of Diacerein on Metabolic Control and Inflammatory Markers in Patients with Type 2 Diabetes Using Antidiabetic Agents: A Randomized Controlled Trial

Table 3

Effect of diacerein on inflammatory markers at end of trial.

	Diacerein ()	Placebo ()	RR (95% CI)	value
(pg/mL)	23 (65.7)	14 (38.9)	1 (1.04–2.1)	0.03
	8 (22.9)	15 (41.7)	0.7 (0.4–1.3)	0.3
	17 (48.6)	14 (38.9)	1.4 (0.9–2.2)	0.19
	6 (17.1)	2 (5.6)	3.1 (0.7–14.8)	0.15
	10 (28.6)	5 (13.9)	1.8 (0.7–4.6)	0.19
	11 (31.4)	6 (16.7)	1.4 (0.8–2.6)	0.3
	6 (17.1)	16 (44.4)	0.6 (0.3–1.2)	0.14
	15 (42.9)	17 (47.2)	0.8 (0.5–1.2)	0.4

Data expressed as n (%) and relative risk (95%CI). Relative risk adjusted for baseline values of the inflammatory markers.